The Malvern, PA-based med tech firm develops tissue reinforcement materials, branded as OviTex,
used in soft tissue reconstruction, including hernia repair, abdominal
wall reconstruction and plastic/reconstruction surgery. They are
currently cleared for sale in the U.S. and have been sold here since
July 2016.
2019 Financials (6 mo.): Revenue: $6.6M (+83%); Operating Expenses: $13.2M (+28%); Net Loss: ($16.0M) (+15%); Cash Flow Ops: ($13.0M) (-20%).
https://seekingalpha.com/news/3506164-tela-bio-readies-ipo
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.